SCHEMBL6096783

SCHEMBL6096783

CCN1C(=O)C(=O)N(c2cc(F)ccc2C)C1=S

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.46
TNFRSF1A P19438 3/20 0.38
P2RX7 Q99572 1/20 0.38
HTR7 P34969 4/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.37
NPC1 O15118 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAPK1 P28482 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 2/20 0.37
HPGD P15428 2/20 0.37
RAB9A P51151 1/20 0.37
POLB P06746 1/20 0.37
KDM4E B2RXH2 2/20 0.36
PKM P14618 2/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6099362 0.83 MEN1 (0.43) TNFRSF1AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL6096771 0.77 NPC1 (0.51) PARK7TNFRSF1AALDH1A1MAPTNPC1
SCHEMBL8714576 0.75 KMT2A (0.47) P2RX7HTR7ALDH1A1MAPTSMN1; SMN2
SCHEMBL6097903 0.74 ALDH1A1 (0.39) TNFRSF1AALDH1A1MAPTNPC1SMN1; SMN2
SCHEMBL6097897 0.71 NPC1 (0.44) TNFRSF1AHTR7ALDH1A1MAPTNPC1
SCHEMBL6068109 0.69 PARK7 (0.42) PARK7ALDH1A1NPC1SMN1; SMN2MEN1
SCHEMBL10450206 0.63 PARK7 (0.62) PARK7ALDH1A1MAPTMAPK1MEN1
SCHEMBL10571542 0.63 MEN1 (0.53) HTR7ALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL20254404 0.63 PARK7 (1.00) PARK7ALDH1A1
SCHEMBL6095067 0.63 MEN1 (0.43) ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135492-B2 Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion WYETH (US) 2006-11-14 US claimed
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis WYETH 2003-06-26 US claimed
US-7135492-B2 Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion WYETH (US) 2006-11-14 US disclosed
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis WYETH 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis FFAR4, FFAR1, MSR1 PARK7 4023/4885TNFRSF1A 3425/4885P2RX7 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.